Genmab's stock rises on cancer data, while Iovance, Coherus tumble

Cancer trial news drove a number of stock moves in both directions over the past 24 hours. Here's a summary of key results and their impact: Genmab shares rise on head and neck cancer data: ...

endpoints.news ·2h ago

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Finance & Markets

Is Alphabet a Stock to Avoid or a Once-in-a-Decade Buy on the Dip?

The stock fell after the company’s latest earnings report.

Alphabet shares fell 20% post-earnings report
AI-driven growth boosts Google Search and advertising revenue
Potential "once-in-a-decade buy" on current dip

2h ago ·fool.com

Is Ares Capital Corp a Buy After Its Latest Earnings Report?

Ares Capital's latest earnings highlighted some concerns about its ability to cover its high-yielding dividend.

Ares Capital's Q3 earnings per share fell to $0.46, below its $0.48 dividend.
CFO Scott Lem says $1.37/share taxable income can sustain dividend.
$2.6B acquisition of MFIC expected to boost future dividends and EPS.

2h ago ·fool.com

Vietnam to overtake Indonesia in per capita GDP in 2026: IMF

2h ago ·asia.nikkei.com

Toyota, Honda, Nissan slash China output as gasoline car market shrinks

2h ago ·asia.nikkei.com

Saudi role vital in stabilizing oil markets, boosting global energy security: expert

Saudi Arabia has played a key role in stabilizing oil markets and ensuring energy security since the onset of the crisis, according to energy expert Dr. Mowafaq Arija.

2h ago ·english.ajel.sa

Walmart Blocks Its Stock From OKX-ICE Tokenized Trading Venue

Walmart, Eli Lilly, Cigna, Carniva,l and Arcos Dorados objected to trading of their shares on the planned OKX-ICE tokenized stock venue, bringing the total to 38.

2h ago ·decrypt.co